WORLD PEPTIDEFOUNDATION

Where is GHRP-6 being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for GHRP-6 →Worldwide registry directory

Scientific intelligence record

Experience 2.0

Growth hormone secretagogue peptide

GHRP-6

Synthetic growth-hormone secretagogue and ghrelin-receptor agonist studied in endocrine and metabolic research.

Record status

Traceability partial

Last meaningful update: 9/20/2026

Evidence searched through:
Not recorded
Assessment updated:
9/20/2026
Documented human review:
No documented human review recorded
Automated scientific assessment:
9/26/2026
AI source check:
9/26/2026

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

500

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

0

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

6

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

26

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observationArchive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

500

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

0

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

6

Independent evidence dossiers covering the major research questions.

Published source records

26

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

0

Conflicting evidence relationships that remain visible.

Research gaps

1

Questions the current record identifies as unresolved.

Connected media

0

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

6 published domain syntheses connected to 0 featured studies

GHRP-6 no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas
Inspect the published evidence record26 governed records · titles, provenance, and original-source linksOpen records ↓
1997Phase 1–2 human evidence

Influence of endogenous cholinergic tone and growth hormone-releasing peptide-6 on exercise induced growth hormone release.

PubMed-indexed clinical trial; comparative study; journal article; randomized controlled trial examining influence of endogenous cholinergic tone and growth hormone-releasing peptide-6 on exercise induced growth hormone release. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
A Nooitgedagt; H P Koppeschaar; W R de Vries; A Sidorowicz; L J Klok; C Dieguez; F Mallo
Source
Clinical endocrinology
DOI
10.1046/j.1365-2265.1997.1080919.x
PubMed
9135702
Open original source
1998Phase 1–2 human evidence

Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation.

PubMed-indexed clinical trial; journal article; randomized controlled trial; research support, u.s. gov't, non-p.h.s.; research support, u.s. gov't, p.h.s. examining growth hormone (gh)-releasing peptide-6 requires endogenous hypothalamic gh-releasing hormone for maximal gh stimulation. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
N Pandya; R DeMott-Friberg; C Y Bowers; A L Barkan; C A Jaffe
Source
The Journal of clinical endocrinology and metabolism
DOI
10.1210/jcem.83.4.4711
PubMed
9543138
Open original source
1995Phase 1–2 human evidence

Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man.

PubMed-indexed clinical trial; journal article; randomized controlled trial; research support, non-u.s. gov't examining growth hormone-releasing peptide-6 stimulates sleep, growth hormone, acth and cortisol release in normal man. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
R M Frieboes; H Murck; P Maier; T Schier; F Holsboer; A Steiger
Source
Neuroendocrinology
DOI
10.1159/000126883
PubMed
7617137
Open original source
1999Phase 1–2 human evidence

Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration.

PubMed-indexed clinical trial; comparative study; journal article examining effects of growth hormone-releasing peptide-6 on the nocturnal secretion of gh, acth and cortisol and on the sleep eeg in man: role of routes of administration. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
R M Frieboes; H Murck; I A Antonijevic; A Steiger
Source
Journal of neuroendocrinology
DOI
10.1046/j.1365-2826.1999.00364.x
PubMed
10336729
Open original source
1997Phase 1–2 human evidence

Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism.

PubMed-indexed clinical trial; comparative study; journal article; randomized controlled trial; research support, non-u.s. gov't examining growth hormone responses to gh-releasing peptide (ghrp-6) in hypothyroidism. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
F R Pimentel-Filho; J C Ramos-Dias; F B Ninno; C F Façanha; B Liberman; A M Lengyel
Source
Clinical endocrinology
DOI
10.1046/j.1365-2265.1997.1270942.x
PubMed
9156038
Open original source
2016Observational human evidence

Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds.

PubMed-indexed journal article examining growth hormone-releasing peptide 6 enhances the healing process and improves the esthetic outcome of the wounds. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Yssel Mendoza Marí; Maday Fernández Mayola; Ana Aguilera Barreto; Ariana García Ojalvo; Yilian Bermúdez Alvarez; Ana Janet Mir Benítez; Jorge Berlanga Acosta
Source
Plastic surgery international
DOI
10.1016/j.bbamcr.2015.10.019
PubMed
27200188
Open original source
2014Observational human evidence

N-aminoimidazolidin-2-one peptidomimetics.

PubMed-indexed journal article; research support, non-u.s. gov't examining n-aminoimidazolidin-2-one peptidomimetics. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Ngoc-Duc Doan; Robert Hopewell; William D Lubell
Source
Organic letters
DOI
10.1021/ol500739k
PubMed
24697286
Open original source
2018Observational human evidence

Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study.

PubMed-indexed journal article examining growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Maday Fernández-Mayola; Lázaro Betancourt; Alicia Molina-Kautzman; Sucel Palomares; Yssel Mendoza-Marí; Dayana Ugarte-Moreno; Ana Aguilera-Barreto; Yilian Bermúdez-Álvarez; Vladimir Besada; Luis J González; Ariana García-Ojalvo; Ana J Mir-Benítez
Source
International wound journal
DOI
10.1155/2016/4361702
PubMed
29464859
Open original source
2006Observational human evidence

Growth hormone releasing peptide-6 acts as a survival factor in glutamate-induced excitotoxicity.

PubMed-indexed journal article; research support, non-u.s. gov't examining growth hormone releasing peptide-6 acts as a survival factor in glutamate-induced excitotoxicity. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Arancha Delgado-Rubín de Célix; Julie A Chowen; Jesús Argente; Laura M Frago
Source
Journal of neurochemistry
DOI
10.1111/j.1471-4159.2006.04122.x
PubMed
17076656
Open original source
2007Observational human evidence

Formation of acylated growth hormone-releasing peptide-6 by poly(lactide-co-glycolide) and its biological activity.

PubMed-indexed journal article; research support, non-u.s. gov't examining formation of acylated growth hormone-releasing peptide-6 by poly(lactide-co-glycolide) and its biological activity. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Dong Hee Na; Jeong Eun Lee; Sun Woo Jang; Kang Choon Lee
Source
AAPS PharmSciTech
DOI
10.2307/1266454
PubMed
17622118
Open original source
2016Observational human evidence

[Time course study of growth hormone releasing peptide-6-induced c-fos expression in neurons of feeding-related nuclei of hypothalamus].

PubMed-indexed journal article examining [time course study of growth hormone releasing peptide-6-induced c-fos expression in neurons of feeding-related nuclei of hypothalamus]. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Yan-Juan Yu; Jing Dong; Zheng-Yao Jiang; Inge Depoortere
Source
Sheng li xue bao : [Acta physiologica Sinica]
PubMed
26915318
Open original source
2025Observational human evidence

Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation.

PubMed-indexed journal article examining growth hormone-releasing peptide 6 (ghrp-6) hydrogel for acute kidney injury therapy via metabolic regulation. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Xiaotong Zhao; Kai Pan; Rui Li; Meina Liu; Duo Li; Pingping Jia; Zhibo Han; Zhong-Chao Han; Zhikun Guo; Zongjin Li; Qiong Li
Source
Journal of nanobiotechnology
DOI
10.1183/13993003.00284-2021
PubMed
41327290
Open original source
2024Observational human evidence

Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms.

PubMed-indexed journal article examining growth hormone releasing peptide-6 (ghrp-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Jorge Berlanga-Acosta; Danay Cibrian; Juan Valiente-Mustelier; José Suárez-Alba; Ariana García-Ojalvo; Viviana Falcón-Cama; Baohong Jiang; Linlin Wang; Gerardo Guillén-Nieto
Source
Frontiers in pharmacology
DOI
10.1155/S1110724302000335
PubMed
38873418
Open original source
1996Observational human evidence

Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency.

PubMed-indexed journal article; review examining growth hormone releasing hexapeptide-6 (ghrp-6) test in the diagnosis of gh-deficiency. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
M Pombo; A Leal-Cerro; J Barreiro; A Peñalva; R Peino; F Mallo; C Dieguez; F F Casanueva
Source
Journal of pediatric endocrinology & metabolism : JPEM
PubMed
8887178
Open original source
2016Observational human evidence

Neuroprotective effect of epidermal growth factor plus growth hormone-releasing peptide-6 resembles hypothermia in experimental stroke.

PubMed-indexed journal article examining neuroprotective effect of epidermal growth factor plus growth hormone-releasing peptide-6 resembles hypothermia in experimental stroke. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
N Subirós; H Pérez-Saad; L Aldana; C L Gibson; W S Borgnakke; D Garcia-Del-Barco
Source
Neurological research
DOI
10.1080/01616412.2016.1235249
PubMed
27665924
Open original source
1993Observational human evidence

GH releasing peptides--structure and kinetics.

PubMed-indexed comparative study; journal article; research support, u.s. gov't, p.h.s. examining gh releasing peptides--structure and kinetics. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
C Y Bowers
Source
The Journal of pediatric endocrinology
DOI
10.1515/jpem.1993.6.1.21
PubMed
8374685
Open original source
2021Observational human evidence

Growth hormone secretagogue peptide-6 enhances oreochromicins transcription and antimicrobial activity in tilapia (Oreochromis sp.).

PubMed-indexed journal article examining growth hormone secretagogue peptide-6 enhances oreochromicins transcription and antimicrobial activity in tilapia (oreochromis sp.). Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Liz Hernández; Hanlet Camacho; Adriana Nuñez-Robainas; Daniel O Palenzuela; Antonio Morales; Liliana Basabe; Fidel Herrera; Osmany Rodrigo; Adrian Rodriguez-Gabilondo; Janet Velázquez; Soraya Piloto; Mario P Estrada
Source
Fish & shellfish immunology
DOI
10.1016/j.fsi.2021.08.011
PubMed
34592474
Open original source
2015Observational human evidence

Growth hormone-releasing peptide-biotin conjugate stimulates myocytes differentiation through insulin-like growth factor-1 and collagen type I.

PubMed-indexed journal article examining growth hormone-releasing peptide-biotin conjugate stimulates myocytes differentiation through insulin-like growth factor-1 and collagen type i. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Chae Jin Lim; Jung Eun Jeon; Se Kyoo Jeong; Seok Jeong Yoon; Seon Deok Kwon; Jina Lim; Keedon Park; Dae Yong Kim; Jeong Keun Ahn; Bong-Woo Kim
Source
BMB reports
DOI
10.1002/pmic.200900826
PubMed
25644636
Open original source
1995Animal research

Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats.

PubMed-indexed journal article examining intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
W Locke; H D Kirgis; C Y Bowers; A A Abdoh
Source
Life sciences
DOI
10.1016/0024-3205(95)00087-9
PubMed
8614257
Open original source
2017Animal research

Growth hormone releasing peptide-6 enhanced antibody titers against subunit antigens in mice (BALB/c), tilapia (Oreochromis niloticus) and African catfish (Clarias gariepinus).

PubMed-indexed journal article; research support, non-u.s. gov't examining growth hormone releasing peptide-6 enhanced antibody titers against subunit antigens in mice (balb/c), tilapia (oreochromis niloticus) and african catfish (clarias gariepinus). Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Rebeca Martínez; Liz Hernández; Lázaro Gil; Yamila Carpio; Antonio Morales; Fidel Herrera; Alina Rodríguez-Mallón; Yeny Leal; Aracelys Blanco; Mario Pablo Estrada
Source
Vaccine
DOI
10.1016/j.vaccine.2017.07.060
PubMed
28893476
Open original source
2004Animal research

Effect of ghrelin and growth hormone-releasing peptide 6 on septic ileus in mice.

PubMed-indexed comparative study; journal article; research support, non-u.s. gov't examining effect of ghrelin and growth hormone-releasing peptide 6 on septic ileus in mice. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
B Y De Winter; J G De Man; T C Seerden; I Depoortere; A G Herman; T L Peeters; P A Pelckmans
Source
Neurogastroenterology and motility
DOI
10.1111/j.1365-2982.2004.00564.x
PubMed
15305999
Open original source
2011Animal research

Insulin and growth hormone-releasing peptide-6 (GHRP-6) have differential beneficial effects on cell turnover in the pituitary, hypothalamus and cerebellum of streptozotocin (STZ)-induced diabetic rats.

PubMed-indexed journal article; research support, non-u.s. gov't examining insulin and growth hormone-releasing peptide-6 (ghrp-6) have differential beneficial effects on cell turnover in the pituitary, hypothalamus and cerebellum of streptozotocin (stz)-induced diabetic rats. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Miriam Granado; Cristina García-Cáceres; María Tuda; Laura M Frago; Julie A Chowen; Jesús Argente
Source
Molecular and cellular endocrinology
DOI
10.1016/j.mce.2011.02.002
PubMed
21352888
Open original source
1995Laboratory research

Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells.

PubMed-indexed journal article; research support, non-u.s. gov't examining growth hormone releasing peptide (ghrp-6) stimulates phosphatidylinositol (pi) turnover in human pituitary somatotroph cells. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
T Lei; M Buchfelder; R Fahlbusch; E F Adams
Source
Journal of molecular endocrinology
DOI
10.1677/jme.0.0140135
PubMed
7772238
Open original source
2024Laboratory research

Calorie restriction activates a gastric Notch-FOXO1 pathway to expand ghrelin cells.

PubMed-indexed journal article; research support, n.i.h., extramural; research support, non-u.s. gov't examining calorie restriction activates a gastric notch-foxo1 pathway to expand ghrelin cells. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Wendy M McKimpson; Sophia Spiegel; Maria Mukhanova; Michael Kraakman; Wen Du; Takumi Kitamoto; Junjie Yu; Zhaobin Deng; Utpal Pajvani; Domenico Accili
Source
The Journal of cell biology
DOI
10.1016/j.stemcr.2018.01.026
PubMed
38958606
Open original source
2005Laboratory research

Growth hormone-releasing peptide-6 increases insulin-like growth factor-I mRNA levels and activates Akt in RCA-6 cells as a model of neuropeptide Y neurones.

PubMed-indexed journal article; research support, non-u.s. gov't examining growth hormone-releasing peptide-6 increases insulin-like growth factor-i mrna levels and activates akt in rca-6 cells as a model of neuropeptide y neurones. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
L M Frago; C Pañeda; J Argente; J A Chowen
Source
Journal of neuroendocrinology
DOI
10.1111/j.1365-2826.2005.01347.x
PubMed
16218998
Open original source
Insufficient evidence

Growth hormone in obesity.

Source reference associated with GHRP-6. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1038/sj.ijo.0800807
PubMed
10193871
Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓
Chemical identity

Molecular and structural record

Structured record
Molecular formula
C46H56N12O6
Molecular weight (Da)
873
InChIKey
WZHKXNSOCOQYQX-UHFFFAOYSA-N

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Research discovery

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

  1. 1993 · study · Temporal status not established

    GH releasing peptides--structure and kinetics.

    The Journal of pediatric endocrinology

  2. 1995 · study · Temporal status not established

    Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man.

    Neuroendocrinology

  3. 1995 · study · Temporal status not established

    Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats.

    Life sciences

  4. 1995 · study · Temporal status not established

    Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells.

    Journal of molecular endocrinology

  5. 1996 · study · Temporal status not established

    Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency.

    Journal of pediatric endocrinology & metabolism : JPEM

  6. 1997 · study · Temporal status not established

    Influence of endogenous cholinergic tone and growth hormone-releasing peptide-6 on exercise induced growth hormone release.

    Clinical endocrinology

  7. 1997 · study · Temporal status not established

    Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism.

    Clinical endocrinology

  8. 1998 · study · Temporal status not established

    Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation.

    The Journal of clinical endocrinology and metabolism

  9. 1999 · study · Temporal status not established

    Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration.

    Journal of neuroendocrinology

  10. 2004 · study · Temporal status not established

    Effect of ghrelin and growth hormone-releasing peptide 6 on septic ileus in mice.

    Neurogastroenterology and motility

  11. 2005 · study · Temporal status not established

    Growth hormone-releasing peptide-6 increases insulin-like growth factor-I mRNA levels and activates Akt in RCA-6 cells as a model of neuropeptide Y neurones.

    Journal of neuroendocrinology

  12. 2006 · study · Temporal status not established

    Growth hormone releasing peptide-6 acts as a survival factor in glutamate-induced excitotoxicity.

    Journal of neurochemistry

  13. 2007 · study · Temporal status not established

    Formation of acylated growth hormone-releasing peptide-6 by poly(lactide-co-glycolide) and its biological activity.

    AAPS PharmSciTech

  14. 2011 · study · Temporal status not established

    Insulin and growth hormone-releasing peptide-6 (GHRP-6) have differential beneficial effects on cell turnover in the pituitary, hypothalamus and cerebellum of streptozotocin (STZ)-induced diabetic rats.

    Molecular and cellular endocrinology

  15. 2014 · study · Temporal status not established

    N-aminoimidazolidin-2-one peptidomimetics.

    Organic letters

  16. 2015 · study · Temporal status not established

    Growth hormone-releasing peptide-biotin conjugate stimulates myocytes differentiation through insulin-like growth factor-1 and collagen type I.

    BMB reports

  17. 2016 · study · Temporal status not established

    Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds.

    Plastic surgery international

  18. 2016 · study · Temporal status not established

    [Time course study of growth hormone releasing peptide-6-induced c-fos expression in neurons of feeding-related nuclei of hypothalamus].

    Sheng li xue bao : [Acta physiologica Sinica]

  19. 2016 · study · Temporal status not established

    Neuroprotective effect of epidermal growth factor plus growth hormone-releasing peptide-6 resembles hypothermia in experimental stroke.

    Neurological research

  20. 2017 · study · Temporal status not established

    Growth hormone releasing peptide-6 enhanced antibody titers against subunit antigens in mice (BALB/c), tilapia (Oreochromis niloticus) and African catfish (Clarias gariepinus).

    Vaccine

  21. 2018 · study · Temporal status not established

    Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study.

    International wound journal

  22. 2021 · study · Temporal status not established

    Growth hormone secretagogue peptide-6 enhances oreochromicins transcription and antimicrobial activity in tilapia (Oreochromis sp.).

    Fish & shellfish immunology

  23. 2024 · study · Temporal status not established

    Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms.

    Frontiers in pharmacology

  24. 2024 · study · Temporal status not established

    Calorie restriction activates a gastric Notch-FOXO1 pathway to expand ghrelin cells.

    The Journal of cell biology

  25. 2025 · study · Temporal status not established

    Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation.

    Journal of nanobiotechnology

  26. 2026 · regulatory · Temporal status not established

    Regulatory review: not_approved

    European Union

  27. 2026 · regulatory · Temporal status not established

    Regulatory review: not_approved

    United States

  28. Date unavailable · study · Temporal status not established

    Growth hormone in obesity.

    other

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Researchers represented in the evidence record12 bibliographic identities · open to inspect

These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.

C Y Bowers

3 represented evidence records

Years represented: 1993, 1995, 1998

Publishing organizations appearing in records: Life sciences, The Journal of clinical endocrinology and metabolism, The Journal of pediatric endocrinology

A Steiger

2 represented evidence records

Years represented: 1995, 1999

Publishing organizations appearing in records: Journal of neuroendocrinology, Neuroendocrinology

Antonio Morales

2 represented evidence records

Years represented: 2017, 2021

Publishing organizations appearing in records: Fish & shellfish immunology, Vaccine

Ariana García-Ojalvo

2 represented evidence records

Years represented: 2018, 2024

Publishing organizations appearing in records: Frontiers in pharmacology, International wound journal

C Dieguez

2 represented evidence records

Years represented: 1996, 1997

Publishing organizations appearing in records: Clinical endocrinology, Journal of pediatric endocrinology & metabolism : JPEM

F Mallo

2 represented evidence records

Years represented: 1996, 1997

Publishing organizations appearing in records: Clinical endocrinology, Journal of pediatric endocrinology & metabolism : JPEM

Fidel Herrera

2 represented evidence records

Years represented: 2017, 2021

Publishing organizations appearing in records: Fish & shellfish immunology, Vaccine

H Murck

2 represented evidence records

Years represented: 1995, 1999

Publishing organizations appearing in records: Journal of neuroendocrinology, Neuroendocrinology

Jesús Argente

2 represented evidence records

Years represented: 2006, 2011

Publishing organizations appearing in records: Journal of neurochemistry, Molecular and cellular endocrinology

Julie A Chowen

2 represented evidence records

Years represented: 2006, 2011

Publishing organizations appearing in records: Journal of neurochemistry, Molecular and cellular endocrinology

Laura M Frago

2 represented evidence records

Years represented: 2006, 2011

Publishing organizations appearing in records: Journal of neurochemistry, Molecular and cellular endocrinology

Liz Hernández

2 represented evidence records

Years represented: 2017, 2021

Publishing organizations appearing in records: Fish & shellfish immunology, Vaccine

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 12 represented connections ↓

institution

Clinical endocrinology

represented evidence source

institution

Journal of neuroendocrinology

represented evidence source

institution

The Journal of clinical endocrinology and metabolism

represented evidence source

institution

Neuroendocrinology

represented evidence source

institution

Plastic surgery international

represented evidence source

institution

Organic letters

represented evidence source

institution

International wound journal

represented evidence source

institution

Journal of neurochemistry

represented evidence source

institution

AAPS PharmSciTech

represented evidence source

institution

Sheng li xue bao : [Acta physiologica Sinica]

represented evidence source

institution

Journal of nanobiotechnology

represented evidence source

institution

Frontiers in pharmacology

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 6 domain conclusions and 0 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the GHRP-6 evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Published jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

European Union

Regulator: Not represented

not_approved

As of: 9/9/2026 · Temporal status not established

Regulatory context incomplete: regulator.

EMA medicines portal

United States

Regulator: Not represented

not_approved

As of: 9/9/2026 · Temporal status not established

Regulatory context incomplete: regulator.

FDA Drugs@FDA / official FDA record

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:24:53 PM

global evidence atlas

GHRP-6 research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

599Discoverable source universe
500Ranked screening records
6Research domains
0Accountably approved conclusions

500 matching records · ranked 2026-09-18

Page 1 of 20

Count reconciliation: 599 discoverable source records match the peptide identity query; 500 are retained in this bounded, ranked screening view; 0 belong to the separate governed layer labeled “Accountably approved conclusions.” Domain totals overlap because one publication may inform several questions.

governance and regulatory context

GHRP-6: what this atlas does and does not establish

Last checked
2026-09-18
Accountable publication approval
Not yet approved by a named accountable reviewer. Machine screening only.

No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.

Regulatory status by jurisdiction

Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.

Known limitations of this pass

  • no patent candidate retained after literal filter

No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review. 2 correction(s) have been recorded against this atlas's source metadata.

GHRP-6 evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

A

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

B

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

C

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

D

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

peptide explorer

Structural visualization and provenance

Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.

Fully specified molecular identity

Molecular formula
C46H56N12O6
Molecular weight
873 g/mol
Exact identity / sequence notation
His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Identity-defining modifications
  • D-Trp2
  • D-Phe5
  • C-terminal amide
PubChem CID
5486806
InChIKey
WZHKXNSOCOQYQX-FUAFALNISA-N

D-residues are exact in notation and represented as X in the schematic.

Sources: NIH PubChem — GHRP-6 · reviewed 2026-09-17

Representative sequence-derived model
Structure source
Generated from this record's governed amino-acid sequence
Identifier
Not applicable — not a database structure
Method
Schematic layout ordered by residue position only; not a molecular-dynamics, homology, or fold prediction
Confidence / limitations
Illustrative only. Not physically accurate; carries no structural, binding-site, or activity meaning.
Provenance
WPF governed PeptideChemistry record
Retrieved / last reviewed
2026-09-17

This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.

Suggested citation

  • APA

    World Peptide Foundation. (n.d.). GHRP-6 — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 20, 2026.) https://www.worldpeptidefoundation.org/directory/ghrp-6

  • AMA / Vancouver

    World Peptide Foundation. GHRP-6 — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 20, 2026. https://www.worldpeptidefoundation.org/directory/ghrp-6